1-2 of 2
Shanthakumar Tyavanagimatt
Close
Sort by
Journal Articles

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

Clinical Trials & Observations
Stephen T. Oh, Ruben A. Mesa, Claire N. Harrison, Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah A. Buckley, Shanthakumar Tyavanagimatt, Bryan G. Harder, Karisse Roman-Torres, Jennifer Smith, Adam R. Craig, John Mascarenhas, Srdan Verstovsek
Journal: Blood Advances
Blood Adv (2023) 7 (19): 5835–5842.
https://doi.org/10.1182/bloodadvances.2023010151
Published: 2023
Includes: Supplemental data
Journal Articles

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

Clinical Trials & Observations
Aaron T. Gerds, Michael R. Savona, Bart L. Scott, Moshe Talpaz, Miklos Egyed, Claire N. Harrison, Abdulraheem Yacoub, Alessandro Vannucchi, Adam J. Mead, Jean-Jacques Kiladjian, Jennifer O’Sullivan, Valentin García-Gutiérrez, Prithviraj Bose, Raajit K. Rampal, Carole B. Miller, Jeanne Palmer, Stephen T. Oh, Sarah A. Buckley, Diane R. Mould, Kaori Ito, Shanthakumar Tyavanagimatt, Jennifer A. Smith, Karisse Roman-Torres, Sri Devineni, Adam R. Craig, John O. Mascarenhas
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5825–5835.
https://doi.org/10.1182/bloodadvances.2020003314
Published: 2020
Includes: Supplemental data